BTXA-51 is under clinical development by Edgewood Oncology and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 38% phase transition success rate ...

Two patients are presented with initially undetermined multisystem neurological disorders and excessive sialorrhoea, later diagnosed as mitochondrial cytopathy, who had side effects after treatment ...

BTXA-51 is under clinical development by Edgewood Oncology and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to GlobalData, ...

While the following burning ban doesn't apply immediately to our usual coverage area, we remain in drought conditions. The ...

【又一“除皱神器”获批！上市企业开启肉毒素竞赛 ...

Dermatitis. 2006;17(4):165-181. There are very few randomized controlled trials that have evaluated treatments of hand dermatitis in general. [61] A review of published trials that involved the ...

财联社9月9日讯（记者 何凡）今日复星医药（600196.SH）官宣旗下注射用A型肉毒毒素已获批，而这也是国内第六款获批的肉毒素。据悉该产品由复星医药产业从美国引进，截至今年7月已累计投入研发费用约4亿元。